Novavax begins final stage COVID-19 vaccine testing

The vaccine from the Gaithersburg, Md.-based drugmaker is the 5th funded by Operation Warp Speed, the governments initiative to speed COVID-19 vaccine development, to reach phase 3 trials. It is among 11 around the world to reach this stage, according to the Times..

Its vaccine provided especially promising arise from earlier trials, as individuals produced high levels of antibodies. A virologist at Weill Cornell Medicine in New York City, John Moore, PhD, informed the Times that Novavaxs vaccine produced “markedly greater” levels of antibodies than any other released outcomes.

Read the full short article here..

Novavax has begun last screening of its COVID-19 vaccine, with one trial happening in the U.K. and another in the U.S. set up to begin next month, The New York Times reported..

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

The trial will likewise be unique because approximately 400 individuals will get a flu shot in addition to the COVID-19 vaccine, the Times reported. Offering the flu shots will help figure out whether its safe to provide two vaccinations simultaneously..

Though Novavax has never ever brought a vaccine to market, the federal government gave the business $1.6 billion in late June to help its trials..

Maia Anderson –
Monday, September 28th, 2020
Print|Email.

Novavaxs phase 3 trial is expected to enroll as much as 10,000 individuals in the U.K., according to the Times..

Novavax stated the stage 3 trial would seek to register at least a quarter of its individuals over the age of 65 and would focus on groups most impacted by COVID-19, consisting of ethnic and racial minorities..

More articles on drug store: FDA, HHS permit states to import drugs from CanadaVaccine advisory panel to postpone vote on who would get COVID-19 vaccine priorityCuomo to form evaluation council for COVID-19 vaccines, says hes cautious of approval process politicization.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by click on this link.